国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
甲氨蝶呤联合米非司酮治疗异位妊娠疗效观察
Observation of Methotrexate and Mifepristone in the Treament of Ectopic Pregnancy
  
DOI:
中文关键词:  甲氨蝶呤  米非司酮  异位妊娠  疗效
英文关键词:Methotrexate  Mifepristone  Ectopic pregnancy  Application effect
基金项目:
作者单位
赵珺 缙云县第二人民医院妇产科(浙江缙云 321404) 
吕荷叶 缙云县第二人民医院妇产科(浙江缙云 321404) 
洪海 辉瑞(北京)国际医学院药物研究中心 。 
摘要点击次数: 899
全文下载次数: 1417
中文摘要:
      摘 要 目的:观察甲氨蝶呤联合米非司酮治疗异位妊娠的临床疗效。方法:58例异位妊娠患者按入院前后次序分为观察组及对照组各29例。对照组予甲氨蝶呤50 mg·m-2,im bid;观察组在对照组基础上,加用米非司酮片50 mg,po bid。两组疗程均为3 d。治疗后比较两组治愈率、二次用药率及不良反应发生率。结果:观察组治愈率为93.1%,高于对照组的69.0%(P<0.05);二次用药率为10.3%,明显低于对照组的48.4%(P<0.05);两组不良反应发生差异无统计学意义(P>0.05)。结论:甲氨蝶呤联合米非司酮治疗异位妊娠效果确切,能明显降低二次用药率,值得临床推广使用。
英文摘要:
      ABSTRACT Objective::To observe the application effect of methotrexate and mifepristone on ectopic pregnancy. Methods:58 cases of ectopic pregnant patients were treated in our hospital from January 2010 to January 2013 according to admission order and divided into study group and control group with 29 cases in either group. The control group was treated with methotrexate intramuscular injection, and based on the treatment of the control group, the study group was treated with mifepristone. At the end of the treatment, the cure rate , secondary compliance rate and adverse reaction rate were compared between the two groups. Results: After the treatment, the cure rate of the study group was 93.1% higher than those of the control group (69%) . The difference was statistically significant (P<0.05). The secondary compliance rate of the study group was only 10.3%, significantly lower than 48.4% of the control group, and the difference was statistically significant (P<0.05). The incidence rate of adverse reaction in the study group was 55.2% and 51.7% in the control group, and there was no significant difference (P>0.05).Conclusion:Methotrexate and mifepristone had their accurate efficacy in the treatment of ectopic pregnancy. They could reduce the secondary compliance rate, and the burden of the patients and their family members. The treament is worthy of clinical use.
查看全文  查看/发表评论  下载PDF阅读器
关闭